Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-cancer therapeutics - Inflection Biosciences/AUM Biosciences

Next Previous
Drug Profile

Research programme: anti-cancer therapeutics - Inflection Biosciences/AUM Biosciences

Alternative Names: IBL-100 series; IBL-300 series; IBL-301

Latest Information Update: 28 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spanish National Cancer Research Centre
  • Developer Inflection Biosciences; Multiple Myeloma Research Foundation; Trinity College Dublin; University of Sydney; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Proto oncogene protein c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Haematological malignancies; Head and neck cancer; Multiple myeloma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for preclinical development in Solid-tumours in Ireland (PO)
  • 28 Feb 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in Australia (PO)
  • 28 Jan 2023 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia(Combination therapy) in Ireland (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top